From LEADERS to LEADERS FREE : A patient centric approach
Chairpersons: Christoph K. NABER, Aaron WONG
Objectives:
To understand how to identify High Bleeding Risk (HBR) patients and what is the prevalence in clinical practiceTo learn how LEADERS FREE impacts current management of HBR patients
To understand how Bleeding Risk status affects stent choice
To explore how Biolimus (BA9) differentiates from other limus drugs and how this may impact clinical outcomes
Lectures
Session objectives
A. Wong
Who are High Bleeding Risk patients? – Experience from LEADERS FREE
M.C. Morice
High Bleeding Risk patients and 1 month DAPT – A paradigm shift with LEADERS FREE
A. Abizaid
High Bleeding Risk or non-High Bleeding Risk? Insights from clinical practice
P.J.L. Ong
Are all limus drugs the same? Impact on clinical outcomes with Biolimus (BA9) stent technology
D. Tresukosol